Phase 3 Chemotherapy-induced Peripheral Neuropathy (CIPN) Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Trial of a Virtual Exercise-based Rehabilitation Program to Treat Persistent Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Chemotherapy-induced Peripheral Neuropathy (CIPN)
University Health Network, Toronto240 enrolled1 locationNCT07481149
Recruiting
Phase 3
GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Qilu Pharmaceutical Co., Ltd.352 enrolled1 locationNCT06994507
Recruiting
Phase 2Phase 3
Gut Microbiome Profiles in Patients with Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).
Chemotherapy-induced Peripheral Neuropathy (CIPN)NumbnessParesthesia+1 more
Bernardino Clavo, MD, PhD42 enrolled1 locationNCT06799351
Recruiting
Phase 2Phase 3
Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy (CIPN)NumbnessParesthesia+1 more
Bernardino Clavo, MD, PhD42 enrolled1 locationNCT06706544